Mineralys Therapeutics Q4 2024 Earnings Report $14.64 -0.36 (-2.37%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Mineralys Therapeutics EPS ResultsActual EPS-$0.98Consensus EPS -$1.00Beat/MissBeat by +$0.02One Year Ago EPSN/AMineralys Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMineralys Therapeutics Announcement DetailsQuarterQ4 2024Date2/12/2025TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptMLYS Earnings History Remove Ads Mineralys Therapeutics Earnings HeadlinesMineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment ProgressMarch 27 at 7:05 PM | msn.comMineralys Therapeutics to Host Conference Call on Advance-HTN and Launch-HTN Clinical Trial Results Featuring Dr. Luke LaffinMarch 27 at 9:03 AM | nasdaq.comPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.March 28, 2025 | Brownstone Research (Ad)Insiders Make Huge Purchases of These 4 Biotech StocksMarch 26 at 8:40 AM | 247wallst.comMineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in MarchMarch 25 at 1:04 PM | insidermonkey.comMineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ETMarch 25 at 8:00 AM | globenewswire.comSee More Mineralys Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mineralys Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mineralys Therapeutics and other key companies, straight to your email. Email Address About Mineralys TherapeuticsMineralys Therapeutics (NASDAQ:MLYS), a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.View Mineralys Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
